Compare AIRI & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | ALLR |
|---|---|---|
| Founded | 1979 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 19.3M |
| IPO Year | 2013 | 2021 |
| Metric | AIRI | ALLR |
|---|---|---|
| Price | $3.31 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 154.2K | ★ 156.2K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,108,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.97 | N/A |
| 52 Week Low | $2.55 | $0.61 |
| 52 Week High | $4.17 | $2.35 |
| Indicator | AIRI | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 67.32 |
| Support Level | $3.18 | $0.99 |
| Resistance Level | $3.34 | $1.31 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 60.92 | 68.24 |
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.